Similar articles

• The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.

  Zhang P. Zhang P. J Biol Regul Homeost Agents. 1999 Oct-Dec;13(4):195-200. J Biol Regul Homeost Agents. 1999. PMID: 10703942 Review.
• Arsenic trioxide for the treatment of acute promyelocytic leukemia.

  Lam MS, Ignoffo RJ. Lam MS, et al. Cancer Pract. 2001 May-Jun;9(3):155-7. doi: 10.1046/j.1523-5394.2001.009003155.x. Cancer Pract. 2001. PMID: 11879303 No abstract available.
• Hyperleukocytosis from arsenic trioxide.

  Levy M, Wofford MM, Powell BL, McLean TW. Levy M, et al. Pediatr Blood Cancer. 2008 Jun;50(6):1265-7. doi: 10.1002/pbc.21532. Pediatr Blood Cancer. 2008. PMID: 18300308
• Arsenic-based therapy benefits leukemia patients.

  [No authors listed] [No authors listed] FDA Consum. 2001 Jan-Feb;35(1):4. FDA Consum. 2001. PMID: 11930925 No abstract available.
• Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.

  Chen Z, Zhao WL, Shen ZX, Li JM, Chen SJ, Zhu J, Lallemand-Breittenbach V, Zhou J, Guillemin MC, Vitoux D, de Thé H. Chen Z, et al. Curr Top Microbiol Immunol. 2007;313:129-44. doi: 10.1007/978-3-540-34594-7_8. Curr Top Microbiol Immunol. 2007. PMID: 17217042 Review.